Stock Analysis: Shake Shack, Starbucks, 3M, Eli Lilly, Gilead Sciences, UnitedHealth

Consumer Discretionary Stocks: Shake Shack & Starbucks

• 💡 Shake Shack is reiterated as overweight by Barclays, despite a recent 7% weekly and 20% monthly decline, with its business fundamentals unchanged and RSI indicating oversold conditions.
• 🎯 While not a perfect trading opportunity due to potential choppiness, it's considered a strong long-term investment.
• 📌 Starbucks is also reiterated as overweight by Barclays and included on Josh Brown's best stocks list.

Industrial Pick: 3M

• 🚀 UBS names 3M a top industrial pick, citing compelling non-volume driven profit improvement opportunities and a CEO hitting the right notes for revenue growth acceleration.
• 📈 The stock is seen as somewhat de-risked due to market sentiment, with the anticipated earnings cuts not yet materializing.
• 📊 While the stock has become more fully valued, the new CEO's demonstrated ability to change the business is a positive catalyst.

Healthcare Stocks: Eli Lilly & Gilead Sciences

• ✅ Gilead Sciences is seeing significant earnings acceleration fueled by its HIV platform, rewarding patient investors.
• 💰 Eli Lilly remains overweight despite becoming more expensive, with the GLP-1 franchise and broader distribution of Zepbound supporting strong projected revenue growth.

Healthcare Services: UnitedHealth

• ⚠️ Mizuho cut UnitedHealth's price target to $600 from $650, citing near-term uncertainty around Medicare and market volatility.
• 📈 Despite the target reduction, the stock is still considered an outperform, with a $600 price target representing a significant gain in the current market.
• 🌟 Management is praised as phenomenal, with identified growth levers supporting the positive outlook.